[go: up one dir, main page]

DK1576967T3 - Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse - Google Patents

Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse

Info

Publication number
DK1576967T3
DK1576967T3 DK04290741T DK04290741T DK1576967T3 DK 1576967 T3 DK1576967 T3 DK 1576967T3 DK 04290741 T DK04290741 T DK 04290741T DK 04290741 T DK04290741 T DK 04290741T DK 1576967 T3 DK1576967 T3 DK 1576967T3
Authority
DK
Denmark
Prior art keywords
protein
fragment
adenylate cyclase
recombinant protein
therapeutic use
Prior art date
Application number
DK04290741T
Other languages
English (en)
Inventor
Xavier-Edmond-Edouard Preville
Claude Leclerc
Daniel Ladant
Benedikt Timmerman
Original Assignee
Pasteur Institut
Bt Pharma
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Bt Pharma, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK1576967T3 publication Critical patent/DK1576967T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK04290741T 2004-03-18 2004-03-18 Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse DK1576967T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04290741A EP1576967B1 (en) 2004-03-18 2004-03-18 Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof

Publications (1)

Publication Number Publication Date
DK1576967T3 true DK1576967T3 (da) 2008-01-21

Family

ID=34833798

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04290741T DK1576967T3 (da) 2004-03-18 2004-03-18 Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse

Country Status (19)

Country Link
US (3) US8628779B2 (da)
EP (3) EP1576967B1 (da)
JP (2) JP5438897B2 (da)
KR (2) KR101382250B1 (da)
CN (1) CN1956730B (da)
AT (1) ATE372784T1 (da)
AU (1) AU2005224036B2 (da)
BR (1) BRPI0508722A (da)
CA (1) CA2559235C (da)
CY (1) CY1107042T1 (da)
DE (1) DE602004008874T2 (da)
DK (1) DK1576967T3 (da)
ES (1) ES2293178T3 (da)
MX (1) MXPA06010469A (da)
PL (1) PL1576967T3 (da)
PT (1) PT1576967E (da)
RU (1) RU2441022C2 (da)
SI (1) SI1576967T1 (da)
WO (1) WO2005089792A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188446B1 (en) 2000-09-15 2009-08-05 Institut Pasteur Proteinaceous vectors for molecule delivery to CD11b expressing cells
SI1576967T1 (sl) 2004-03-18 2008-02-29 Pasteur Institut Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe
EP2656842B1 (en) * 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP1894941A1 (en) * 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
WO2008025848A2 (en) * 2006-09-01 2008-03-06 Bt Pharma Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
WO2008147187A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
WO2009013018A2 (en) * 2007-07-24 2009-01-29 Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre Compositions and methods for generating an immune response in a subject
JP5770711B2 (ja) * 2009-03-23 2015-08-26 アンスティテュ パストゥール 細胞中への免疫原性分子のデリバリーに適したＣｙａＡポリペプチド突然変異体及びポリペプチド誘導体
JP5964233B2 (ja) * 2009-09-11 2016-08-03 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． Ｈｐｖにより惹起される疾患の治療用組成物
WO2012006727A1 (en) * 2010-07-15 2012-01-19 British Columbia Cancer Agency Branch Human papillomavirus e7 antigen compositions and uses thereof
EP2478915A1 (en) * 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
ES2670095T3 (es) 2011-06-17 2018-05-29 Universiteit Gent Vacunas contra Chlamydia
AU2012356969B2 (en) * 2011-12-21 2017-05-04 Nykode Therapeutics ASA Vaccines against HPV
EP2687849A1 (en) * 2012-07-20 2014-01-22 ISA Pharmaceuticals B.V A process for providing an optimized immune therapy composition
EP2689786A1 (en) 2012-07-23 2014-01-29 Genticel HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
EP2690172A1 (en) * 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
US10018629B2 (en) 2013-08-08 2018-07-10 Institute Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus
EP2975120A1 (en) 2014-07-17 2016-01-20 Institut Pasteur Monomeric and functional adenylate cyclase CyaA toxin
US10420826B2 (en) 2014-11-11 2019-09-24 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
EP3037103A1 (en) 2014-12-23 2016-06-29 Genticel Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV
AU2016232280B2 (en) * 2015-03-16 2018-05-31 Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
EP3463444B1 (en) * 2016-06-07 2024-10-16 Deutsches Krebsforschungszentrum Improvement of hpv l2 peptide immunogenicity
EP3323426A1 (en) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3342421A1 (en) 2016-12-27 2018-07-04 Genticel Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response
JP7423554B2 (ja) * 2018-05-30 2024-01-29 ドイチェス クレブスフォルシュンクスツェントルム 予防用及び治療用の組み合わせワクチン
WO2021063917A1 (en) 2019-10-01 2021-04-08 Universiteit Gent Vaccine against chlamydia in swine
WO2024227236A1 (en) * 2023-04-30 2024-11-07 Instituto Butantan Recombinant protein, expression cassette, immunogenic composition and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
ATE368113T1 (de) * 1992-04-21 2007-08-15 Pasteur Institut Rekombinante mutanten zur induktion spezifischer immunantworten
EP1188446B1 (en) * 2000-09-15 2009-08-05 Institut Pasteur Proteinaceous vectors for molecule delivery to CD11b expressing cells
EP1434859A2 (en) * 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1489092A1 (en) 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
JP4976853B2 (ja) * 2003-11-21 2012-07-18 インスティチュート・パスツール ボルデテラ（Ｂｏｒｄｅｔｅｌｌａ）の組換えアデニル酸シクラーゼ毒素は腫瘍抗原に対するＴ細胞応答を誘発する
SI1576967T1 (sl) 2004-03-18 2008-02-29 Pasteur Institut Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe
EP1894941A1 (en) * 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
DK2233569T3 (da) 2009-03-23 2014-10-06 Inst Of Microbiology Of The Ascr V V L Mutante CyaA-polypeptider og polypeptidderivater egnet til at levere immunogene molekyler i en celle

Also Published As

Publication number Publication date
KR20130079671A (ko) 2013-07-10
KR20070031889A (ko) 2007-03-20
CA2559235A1 (en) 2005-09-29
RU2006131598A (ru) 2008-04-27
ES2293178T3 (es) 2008-03-16
JP2013176390A (ja) 2013-09-09
DE602004008874D1 (de) 2007-10-25
JP2007533307A (ja) 2007-11-22
US8637039B2 (en) 2014-01-28
US20070072266A1 (en) 2007-03-29
EP1725259B1 (en) 2018-02-21
EP2351580A1 (en) 2011-08-03
DE602004008874T2 (de) 2008-06-12
AU2005224036B2 (en) 2011-10-20
RU2441022C2 (ru) 2012-01-27
CN1956730A (zh) 2007-05-02
BRPI0508722A (pt) 2007-08-14
CN1956730B (zh) 2012-04-25
JP5438897B2 (ja) 2014-03-12
EP1725259A1 (en) 2006-11-29
PT1576967E (pt) 2007-12-03
MXPA06010469A (es) 2007-07-04
US20110171244A1 (en) 2011-07-14
AU2005224036A1 (en) 2005-09-29
KR101382250B1 (ko) 2014-04-24
SI1576967T1 (sl) 2008-02-29
JP5824474B2 (ja) 2015-11-25
KR101495740B1 (ko) 2015-02-25
EP2351580B1 (en) 2017-09-20
ATE372784T1 (de) 2007-09-15
US20140227308A1 (en) 2014-08-14
WO2005089792A1 (en) 2005-09-29
US9387243B2 (en) 2016-07-12
EP1576967B1 (en) 2007-09-12
PL1576967T3 (pl) 2008-03-31
US8628779B2 (en) 2014-01-14
CA2559235C (en) 2015-06-16
CY1107042T1 (el) 2012-09-26
EP1576967A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
DK1576967T3 (da) Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse
EA201100072A1 (ru) Новые композиции и способы
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
WO2005012350A3 (en) Epha2 t-cell epitope agonists and uses therefor
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
WO2005012337A3 (en) Antigenic peptides of sars coronavirus and uses thereof
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
NO20065366L (no) Antistoffer og molekyler som er avledet fra disse som binder til STEAP-1-proteiner
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
DE602004018141D1 (de) Polypeptide mit bindungsaffinität für her2
EA201100071A1 (ru) Новые композиции и способы
MX2008009886A (es) Anticuerpos que enlazan par-2.
HK1097854A1 (en) Surface-located campylobacter jejuni polypeptides
WO2008012362A3 (en) New protein isoforms and uses thereof
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
NO20071789L (no) Fremgangsmate for anvendelse av dodsreseptorligander og CD20-antistoffer
BRPI0906997A2 (pt) Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica
EP2322931A3 (en) Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
PE20141565A1 (es) Metodos para detectar papilomavirus humano y proporcionar pronostico para carcinoma de celulas escamosas de cabeza y cuello
BRPI0518571A2 (pt) peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer
ES2421885T3 (es) Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia
ATE554793T1 (de) Konjugat
GB2446748A (en) Vaccine